MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,227.42 +19.31 (+1.60%)
Streaming Delayed Price Updated: 3:26 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
News headline image
Eli Lilly Just Launched Its $149 Obesity Pill ↗
Eli Lilly launches Foundayo weight-loss pill after FDA approval, priced from $149/month, as competition with Novo Nordisk intensifies. 
Via Benzinga
News headline image
What to Expect From Eli Lilly's Next Quarterly Earnings Report
Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings. 
Via Barchart.com
Topics ETFs
News headline image
What's Going On With GoodRx Stock Thursday? ↗
GoodRx shares rise after expanding Eli Lilly's GLP-1 access; analysts keep Buy rating ahead of May earnings. 
Via Benzinga
News headline image
Eli Lilly Faces Pressure In India As Cheaper GLP-1 Rivals Dent Mounjaro Sales ↗
Eli Lilly and Co. is facing mounting pressure in India as a surge rise in lower-cost generic alternatives dent sales. 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the... 
Via MarketMinute
News headline image
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? ↗
One of these players is well-positioned for market leadership. 
Via The Motley Fool
News headline image
Looks Like M&A Week in 3 Different Sectors ↗
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry. 
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why AC Immune Stock Zoomed Almost 15% Higher Today ↗
It's getting a cash infusion from its giant pharmaceutical partner. 
Via The Motley Fool
News headline image
Great News for Eli Lilly Stock Investors! ↗
The weight loss segment is poised to generate lucrative profits for Eli Lilly. 
Via The Motley Fool
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets MASLD and GLP-1 Imaging Bottleneck With TAEUS® as Stocks Under $5 Gain Attention Inside
Via AB Newswire
News headline image
Is Eli Lilly Stock a Buy After a Brand New Approval? ↗
The stock's dip might be an opportunity. 
Via The Motley Fool
News headline image
The AI Engine: S&P 500 Defies Gravity with 13.3% Q4 Growth as Tech Titans Carry the Weight
The fourth-quarter 2025 earnings season has officially drawn to a close, leaving market analysts and investors in awe of the S&P 500’s resilience. Defying high interest rates and a cooling labor... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects 
Via TheNewswire.com
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
Via MarketMinute
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Productivity Surge and Falling Jobless Claims: The New U.S. Labor Paradigm
The United States labor market is currently defying traditional economic gravity, showcasing a resilient "low-hire, low-fire" dynamic that has left analysts and investors recalibrating their... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
S&P 500 Snaps Five-Week Slump with 3.4% Tech-Led Surge Amid Middle East De-escalation Hopes
The S&P 500 (NYSEARCA:SPY) concluded the week ending April 4, 2026, with a resounding 3.4% rally, marking its strongest weekly performance since late 2025. This surge effectively halted a grueling... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market
As the second quarter of 2026 kicks off, the investment landscape is being defined by a renewed sense of optimism from Wall Street’s most influential voices. Goldman Sachs (NYSE: GS) has officially... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals? ↗
Via MarketBeat
News headline image
2 Cash-Producing Stocks with Impressive Fundamentals and 1 We Brush Off
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
Topics Artificial Intelligence
News headline image
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗
The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron. 
Via The Motley Fool
News headline image
The Next Big AI Winner Might Not Be a Tech Company
Lilly’s AI push shows how non-tech firms can dominate the next wave. 
Via Barchart.com
Topics Artificial Intelligence
News headline image
The Second-Best Performing Vanguard ETF Over the Last Decade Is Issuing a 5-For-1 Stock Split. Here's Why It's a Screaming Buy in April. ↗
The Vanguard Mega Cap Growth ETF is down big from its highs as the largest tech stocks lead the broader market sell-off. 
Via The Motley Fool
Topics ETFs
News headline image
Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
As of April 3, 2026, the financial landscape is witnessing a historic disconnect between gritty macroeconomic headlines and exuberant corporate fundamentals. Despite a backdrop of stubborn... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗
The drugmaker hasn't said its last word yet, as the weight-loss drug battle continues to heat up. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story